AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$294.55−0.48 (-0.16%)
Close on Nov 16, 2026Market cap $520.50BP/E 83.2Yield 2.26%
AbbVie EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
AbbVie's EV/EBITDA was 34.8× on Nov 11, 2026, against 51.6× a year earlier. Over the last 5 years it ranged from 17.3× to 51.8×, with a median of 28.1×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 34.8× | −17.0 |
| 2025 | Dec 31, 2025 | 51.8× | +24.4 |
| 2024 | Dec 31, 2024 | 27.4× | +6.0 |
| 2023 | Dec 29, 2023 | 21.4× | +1.9 |
| 2022 | Dec 30, 2022 | 19.5× | +0.9 |
| 2021 | Dec 31, 2021 | 18.6× | −3.0 |
| 2020 | Dec 31, 2020 | 21.6× | −2.6 |
| 2019 | Dec 31, 2019 | 24.2× | +7.6 |
| 2018 | Dec 31, 2018 | 16.7× | −1.6 |
| 2017 | Dec 29, 2017 | 18.2× | +3.8 |
| 2016 | Dec 30, 2016 | 14.4× | −9.4 |
| 2015 | Dec 31, 2015 | 23.8× | +2.9 |
| 2014 | Dec 31, 2014 | 21.0× | +5.9 |
| 2013 | Dec 31, 2013 | 15.1× | – |
See a number that looks wrong?